834861-78-8

Basic information

• Product Name: 2-(3-bromophenyl)ethanethioamide
• Synonyms: 2-(3-bromophenyl)ethanethioamide
• CAS NO: 834861-78-8
• Molecular Formula: C₈H₈BrNS
• Molecular Weight: 230.12482
• Mol File: 834861-78-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-bromophenyl)ethanethioamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-bromophenyl)ethanethioamide(834861-78-8)
• EPA Substance Registry System: 2-(3-bromophenyl)ethanethioamide(834861-78-8)

Safety Data

• Hazardous Substances Data: 834861-78-8(Hazardous Substances Data)

Usage

Type of compound

Thioamide derivative

Key structural feature

Contains a sulfur atom

Usage

Building block in the synthesis of various organic compounds in medicinal chemistry and pharmaceutical research

Potential applications

Development of new drugs and pharmaceuticals

Importance in research

Valuable tool for chemical synthesis and organic chemistry research due to its unique structure and reactivity.

Upstream product

• 31938-07-5 (3-bromophenyl)acetonitrile 
• 1878-67-7 3-Bromophenylacetic acid 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 
• 60312-83-6 2-(3-bromophenyl)acetamide 

Downstream Products

• 250258-70-9 2-{2-[2-(3-bromo-benzyl)-thiazol-4-yl]-ethyl}-isoindole-1,3-dione 
• 954241-25-9 C₁₃H₁₂BrNO₂S 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Histamine H1 receptor ligands. Part I. Novel thiazol-4-ylethanamine derivatives: Synthesis and in vitro pharmacology

A series of 2-substituted thiazol-4-ylethanamines have been synthesized and tested for their histaminergic H1-receptor activities. The compounds with 2-phenyl substitution, regardless of the different physicochemical properties of the meta-substituents at the phenyl ring, showed weak H1-agonistic activity with pD2 values ranging from 4.35 to 5.36. When the phenyl group was replaced by a benzyl group, the resulting compounds all exhibited weak H1-antagonistic activity (pA2: 4.14-4.82). Copyright (C) 1999 Elsevier Science S.A.